Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity

MLA

Bognàr, Tim, et al. “Association of Busulfan Exposure and Outcomes after HCT for Patients with an Inborn Error of Immunity.” Blood Advances, vol. 8, no. 19, Oct. 2024, pp. 5137–45. EBSCOhost, https://doi.org/10.1182/bloodadvances.2024013275.

APA

Bognàr, T., Garcia-Rosa, M., Lalmohamed, A., Güngör, T., Hauri-Hohl, M., Prockop, S., Oram, L., Pai, S.-Y., Brooks, J., Savic, R. M., Dvorak, C. C., Long-Boyle, J. R., Krajinovic, M., Bittencourt, H., Teyssier, A.-C., Théorêt, Y., Martinez, C., Egberts, T. C. G., Morales, E., … Bartelink, I. H. (2024). Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity. Blood Advances, 8(19), 5137–5145. https://doi.org/10.1182/bloodadvances.2024013275

Chicago

Bognàr, Tim, Moises Garcia-Rosa, Arief Lalmohamed, Tayfun Güngör, Mathias Hauri-Hohl, Susan Prockop, Layne Oram, et al. 2024. “Association of Busulfan Exposure and Outcomes after HCT for Patients with an Inborn Error of Immunity.” Blood Advances 8 (19): 5137–45. doi:10.1182/bloodadvances.2024013275.